Suppr超能文献

加拿大儿科神经肿瘤学实践标准

Canadian Pediatric Neuro-Oncology Standards of Practice.

作者信息

Bennett Julie, Erker Craig, Lafay-Cousin Lucie, Ramaswamy Vijay, Hukin Juliette, Vanan Magimairajan I, Cheng Sylvia, Coltin Hallie, Fonseca Adriana, Johnston Donna, Lo Andrea, Zelcer Shayna, Alvi Saima, Bowes Lynette, Brossard Josée, Charlebois Janie, Eisenstat David, Felton Kathleen, Fleming Adam, Jabado Nada, Larouche Valérie, Legault Geneviève, Mpofu Chris, Perreault Sébastien, Silva Mariana, Sinha Roona, Strother Doug, Tsang Derek S, Wilson Beverly, Crooks Bruce, Bartels Ute

机构信息

Division of Neuro-Oncology, The Hospital for Sick Children, Toronto, ON, Canada.

Division of Pediatric Hematology/Oncology, IWK Health Centre, Halifax, NS, Canada.

出版信息

Front Oncol. 2020 Dec 22;10:593192. doi: 10.3389/fonc.2020.593192. eCollection 2020.

Abstract

Primary CNS tumors are the leading cause of cancer-related death in pediatrics. It is essential to understand treatment trends to interpret national survival data. In Canada, children with CNS tumors are treated at one of 16 tertiary care centers. We surveyed pediatric neuro-oncologists to create a national standard of practice to be used in the absence of a clinical trial for seven of the most prevalent brain tumors in children. This allowed description of practice across the country, along with a consensus. This had a multitude of benefits, including understanding practice patterns, allowing for a basis to compare in future research and informing Health Canada of the current management of patients. This also allows all children in Canada to receive equivalent care, regardless of location.

摘要

原发性中枢神经系统肿瘤是儿童癌症相关死亡的主要原因。了解治疗趋势对于解读全国生存数据至关重要。在加拿大,患有中枢神经系统肿瘤的儿童在16个三级护理中心之一接受治疗。我们对儿科神经肿瘤学家进行了调查,以制定一项全国性的实践标准,用于在缺乏针对儿童中七种最常见脑肿瘤的临床试验时使用。这使得能够描述全国范围内的实践情况,并达成共识。这有诸多益处,包括了解实践模式、为未来研究提供比较基础以及向加拿大卫生部通报患者的当前管理情况。这也使加拿大所有儿童,无论身处何地,都能获得同等的护理。

相似文献

1
Canadian Pediatric Neuro-Oncology Standards of Practice.
Front Oncol. 2020 Dec 22;10:593192. doi: 10.3389/fonc.2020.593192. eCollection 2020.
2
Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy.
J Pathol. 2020 Jul;251(3):249-261. doi: 10.1002/path.5457. Epub 2020 Jun 10.
3
Current practice of cancer predisposition testing in pediatric patients with CNS tumors in the United States.
Pediatr Blood Cancer. 2024 Jan;71(1):e30725. doi: 10.1002/pbc.30725. Epub 2023 Oct 20.
4
Review of imaging recommendations from Response Assessment in Pediatric Neuro-Oncology (RAPNO).
Pediatr Radiol. 2023 Dec;53(13):2723-2741. doi: 10.1007/s00247-023-05780-w. Epub 2023 Oct 21.
5
Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile.
JCO Glob Oncol. 2021 Mar;7:425-434. doi: 10.1200/GO.20.00430.
6
Radiotherapy for pediatric central nervous system tumors: a regional cancer centre experience.
J Neurooncol. 2004 Jul;68(3):285-94. doi: 10.1023/b:neon.0000033386.38403.3b.
8
Indian Society of Neuro-Oncology consensus guidelines for the contemporary management of medulloblastoma.
Neurol India. 2017 Mar-Apr;65(2):315-332. doi: 10.4103/0028-3886.201841.

引用本文的文献

5
Applications of machine learning to MR imaging of pediatric low-grade gliomas.
Childs Nerv Syst. 2024 Oct;40(10):3027-3035. doi: 10.1007/s00381-024-06522-5. Epub 2024 Jul 8.
6
Advances in pediatric gliomas: from molecular characterization to personalized treatments.
Eur J Pediatr. 2024 Jun;183(6):2549-2562. doi: 10.1007/s00431-024-05540-4. Epub 2024 Apr 1.
7
Current Molecular and Clinical Landscape of ATRT - The Link to Future Therapies.
Cancer Manag Res. 2023 Dec 7;15:1369-1393. doi: 10.2147/CMAR.S379451. eCollection 2023.
8
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
J Neurooncol. 2023 Feb;161(3):525-538. doi: 10.1007/s11060-023-04241-6. Epub 2023 Feb 1.
9
Pearls & Oy-sters: Salt and Pepper Sign, PLNTY for Drug-Resistant Epilepsy.
Neurology. 2023 Apr 18;100(16):791-795. doi: 10.1212/WNL.0000000000206782. Epub 2022 Dec 23.
10
Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.
Front Oncol. 2022 Sep 23;12:960509. doi: 10.3389/fonc.2022.960509. eCollection 2022.

本文引用的文献

1
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
JCO Precis Oncol. 2020 May 20;4. doi: 10.1200/PO.19.00298. eCollection 2020.
2
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.
Cancer Cell. 2020 Apr 13;37(4):569-583.e5. doi: 10.1016/j.ccell.2020.03.011.
3
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.
Cancer Discov. 2020 Jul;10(7):942-963. doi: 10.1158/2159-8290.CD-19-1030. Epub 2020 Apr 1.
5
Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.
Neuro Oncol. 2020 May 15;22(5):613-624. doi: 10.1093/neuonc/noz235.
8
Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
J Neurooncol. 2019 Nov;145(2):375-383. doi: 10.1007/s11060-019-03307-8. Epub 2019 Oct 16.
9
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
Nat Commun. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验